Due to the actions of a 3rd party, our laboratory software is unable to process orders at our normal capacity. This is not a data breach. If this affects your laboratory orders, we will contact you directly. You do not need to call the practice.

Clinical Trials & Research

19043 - Ph2 IMMU-132 met Solid Tumors

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors (IMMU-132-11)

Disease Types: Solid Tumors,&nbs

Available at: {clinical_trial_location backspace="7"}19043 - Ph2 IMMU-132 met Solid Tumors, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}